| |
|
|
|
|
|
|
|||
|
KS Gulliya and S Pervaiz
Baylor Research Foundation, Baylor University Medical Center, Dallas, TX
75246.
Laser photoradiation therapy was tested in an in vitro model for its
efficacy in the elimination of non-Hodgkin's lymphoma cells. Results show
that at 31.2 J/cm2 of laser light in the presence of 20 micrograms/mL of
merocyanine 540 (MC540) there was greater than 5 log reduction in Burkitt's
lymphoma (Daudi) cells. Similar tumor cell kill was obtained for leukemia
(HL-60) cells at a laser light dose of 93.6 J/cm2. However, to obtain the
same efficiency of killing for histiocytic lymphoma (U-937) cells, a higher
dose of MC540 (25 micrograms/mL) was required. Clonogenic tumor stem cell
colony formation was reduced by greater than 5 logs after laser
photoradiation therapy. Under identical conditions for each cell line the
percent survival for granulocyte-macrophage colony-forming units (CFU-GM,
45.9%, 40%, 17.5%), granulocyte/erythroid/macrophage/megakaryocyte (GEMM,
40.1%, 20.1%, 11.5%), colony-forming units (CFU-C, 16.2%, 9.1%, 1.8%), and
erythroid burst-forming units (BFU-E, 33.4%, 17.8%, 3.9%) was significantly
higher than the tumor cells. Mixing of gamma ray- irradiated normal marrow
cells with tumor cells (1:1 and 10:1 ratio) did not interfere with the
elimination of tumor cells. The effect of highly purified recombinant
interferon alpha (rIFN) on laser photoradiation therapy of tumor cells was
also investigated. In the presence of rIFN (30 to 3,000 U/mL), the
viability of leukemic cells was observed to increase from 0% to 1.5% with a
concurrent decrease in membrane polarization, suggesting an increase in
fluidity of cell membrane in response to rIFN. However, at higher doses of
rIFN (6,000 to 12,000 U/mL) this phenomenon was not observed. The viability
of lymphoma cells remained unaffected at all doses of rIFN tested. These
results may have therapeutic relevance in patients undergoing interferon
treatment who require bone marrow transplantation, as the complete
elimination of tumor cells by marrow-purging procedures may be hampered by
this increased survival in the presence of interferon.
This article has been cited by other articles:
| |||||||||||
| Copyright © 1989 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||